AC Immune SA

AC Immune SA, à Ecublens (VD), CHE-109.878.825 (FOSC du 30.07.2025, p. 0/1006398156). Maurer Matthias est maintenant à Pully.

AC Immune SA, à Ecublens (VD), CHE-109.878.825 (FOSC du 13.03.2025, p. 0/1006281509). Williams Douglas, Lanthaler Werner, et Shaw Monica ne sont plus administrateurs;
leur signature est radiée. Post Anke n'est plus directrice;
sa signature est radiée. PricewaterhouseCoopers SA (CHE-497.306.752) a transféré son siège à Lausanne. Zügel Martin, de Allemagne, à Cologne (Allemagne), président, avec signature collective à deux, et Aguiar Lucander Renée, de Suède, à Stockholm (Suède), avec signature collective à deux, sont membres du conseil d'administration.

Category: Notifications issued to company members/nSub-category: Invitation to the General Meeting/nPublication date: SHAB 19.05.2025/nPublicly viewable until: 19.05.2026/nPublication number: UP04-0000007201/nPublishing entity/nAC Immune SA, (AC Immune AG) (AC Immune Ltd), EPFL Innovation Park, Bâtiment B.

1015 Lausanne/nInvitation to the ordinary general meeting AC/nImmune SA/nOrganisation concerned:
/nAC Immune SA/nCHE-109.878.825/nEPFL Innovation Park.

bâtiment B/n1015 Lausanne/nGeneral meeting details:
/n19.06.2025, 14.00 Uhr.

EPFL Innovation Park/nBuilding D/nPluton Conference Room/n1015 Lausanne/nSwitzerland/nInvitation/Agenda:
/nInvitation to the Annual General Meeting 2025/n1. 2024 IFRS Consolidated Financial Statements, 2024 Statutory Financial/nStatements, 2024 Compensation Report/n1.1 Approval of 2024 IFRS Consolidated Financial Statements and 2024 Statutory/nFinancial Statements/n1.2 Advisory vote on the 2024 Compensation Report/n2. Appropriation of Losses/n3. Discharge of the Members of the Board of Directors and the Executive/nCommittee/n4. Compensation for the Members of the Board of Directors and the Executive/nCommittee/n4.1 Binding vote on maximum aggregate compensation for Members of the Board of/nDirectors from the AGM 2025 to the AGM 2026/n4.2 Binding vote on maximum aggregate compensation for Members of the Executive/nCommittee for the financial year 2026/n5. Re-elections and Elections/n5.1 Re-elections of Members of the Board of Directors/n5.2 Elections of Members and the Chair of the Board of Directors/n5.3 Re-elections of Members of the Compensation, Nomination & Corporate Governance/nCommittee/n5.4 Election of Member of the Compensation, Nomination & Corporate Governance/nCommittee/n5.5 Re-election of the Statutory Auditors/n5.6 Re-election of the Independent Proxy/n6. Changes in the Articles of Association/n6.1 Capital band (Article 3a)/n6.2 Increase and amendment of conditional share capital for employee-benefit plans/n(Article 3c paras. 1 and 3)/nINVITATION TO THE/nANNUAL GENERAL/nMEETING 2025/nto the Shareholders of AC Immune SA/nThursday.

19 June 2025/n2:
00pm CEST/n8:00am EST/nOur goal is global leadership in Precision/nMedicine for the diagnosis and treatment/nof neurodegenerative diseases/nwe are executing a clear business strategy built on three pillars:/naccelerate development of novel/ntherapeutics in ad with our partners/nexpand our strategic focus in parkinson's disease (pd) and non-ad/nneurodegenerative diseases, including neuroorphan indications/nand limbic-predominant age-related tdp-43 encephalopathy (late)/na continued focus on diagnostics enabling precision medicine/nto be an ultimate differentiator for the company/nalzheimer's disease/nparkinson's and neuro orphans/ndiagnostics/nContents/nLetter to shareholders 2/nOverview 4/nagenda & proposals/nAgenda & proposals 6/n1. 2024 IFRS Consolidated Financial Statements,/n2024 Statutory Financial Statements,/n2024 Compensation Report 6/n2. Appropriation of losses 6/n3. Discharge of the Members of the Board of/nDirectors and the Executive Committee 7/n4. Compensation for the Members of the Board of/nDirectors and the Executive Committee 7/n5. Re-elections and elections 8/n6. Changes in the Articles of Association 10/norganizational notes/nOrganizational notes 14/nLegal notes 16/nsay on pay/nShareholder information on/ncompensation proposals 18/n1/n| ac immune invitation to the annual general meeting 2025/nLetter to shareholders/nDear Shareholders,/nWe are pleased to hold AC Immune's 9th Annual General Meeting (AGM) as a public company, and/nwe are happy to invite you to attend the meeting in person. For those who cannot attend in person,/nwe kindly invite you to vote through the elected Independent Proxy./nWe are delighted to present to you our 2024 IFRS Consolidated/nFinancial Statements and Statutory Financial Statements to be/napproved by shareholders. This year's Annual Report again/ncontains our Environmental, Social and Governance Report./nIn review, 2024 was a year of extraordinary progress for the/nCompany including several exceptional achievements in our/npipeline, particularly our active immunotherapies. We continue/nto reinforce our leadership in the field of neurodegenerative/ndiseases (NDDs) and the delivery of Precision Prevention./nour leadership in active immunotherapies for/nndds has been clearly demonstrated again/nWe are making great strides on our three active immuno-/ntherapies targeting the hallmark pathological proteins, Abeta/n(ACI-24.060), pTau (ACI-35.030), and a-syn (ACI-7104.056), and/nleading the way towards delivering innovative new approaches/nto Alzheimer's disease (AD), Parkinson's disease (PD), and/npotentially other NDDs./nFor ACI-35.030, patients are being treated with JNJ-2056 in the/nlarge, randomized Phase 2b clinical trial program (ReTain)/nin preclinical AD being conducted by our partner, Janssen/nPharmaceuticals (J&J). This is a first-of-its-kind clinical trial in/nindividuals with pre-symptomatic AD who are selected using/na multistep screening protocol. The extremely high level of/ninterest in this trial has resulted in the screening of many/nthousands of presymptomatic people to identify those with/nmeasurable Tau pathology. We were delighted in September/n2024 to receive a CHF 25 million milestone payment in/nrecognition of the strong interest in the study./nOur innovative, biomarker-based adaptive Phase 1b/2 clinical/ntrial, ABATE, evaluating our anti-Abeta active immunotherapy,/nACI-24.060, in patients with prodromal AD and individuals/nwith Down syndrome is progressing well. ACI-24.060 is FDA/nFast Track designated and now progressing with close/ninvolvement of Takeda following the exclusive option and/nlicense deal signed in May 2024. The 12-month treatment/ntimepoint will be reached for the first 3 AD cohorts in the/nABATE study in December 2025 with interim results reported/nshortly thereafter./nWe were proud to report in November 2024 the initial interim/nresults from our Phase 2 VacSYn trial of ACI-7104.056, our/nwholly-owned a-syn targeted active immunotherapy for/nearly-stage PD. Following an additional immunization in the/ntrial, further positive immunogenicity and good safety data/nwere presented at the AD/PD 2025 Conference in Vienna./nACI-7104.056 has been well tolerated and safely generated/na strong antibody response against a-syn. We hope to launch/nthe larger Part 2 of the trial to establish proof-of-concept later/nin 2025./nThese programs in preclinical AD, in prodromal AD, and in/nearly-stage PD, respectively, underscore our long-term drive/nto deliver precisely targeted active immunotherapy aiming/nto prevent the irreversible neurological damage caused/nby NDDs./nDouglas Williams, Chair Andrea Pfeifer, Chief Executive Officer/n2/nac immune invitation to the annual general meeting 2025 | letter to shareholders/nprecision prevention with active immuno-/ntherapy and small molecule drugs/nWhile the disease-modifying potential of immunotherapeutic/napproaches has been demonstrated with the regulatory/napproval of monoclonal antibody-based therapies for AD, we/nbelieve the early commercial uptake of these products has/nbeen slower than anticipated based in part on issues of patient/ninconvenience and ongoing risk-benefit uncertainties. We are/nmore convinced than ever that active immunotherapy, where/nwe are leading the way, is the optimal immunotherapeutic/nmodality providing the right features for a precision-based/npreventive approach in neurodegenerative disease. Success/nin our efforts with our partners will see AC Immune's programs/nhave a profound social and economic impact with potential/nto be employed across the global population./nAdditionally, we are developing small molecule drugs to/ncomplement the immunotherapeutic approaches, particularly/nin some early stages of diseases with intracellular pathology./nWe are very encouraged by our raft of small molecule/ndrug candidates coming through preclinical development/ntargeting Tau, a-syn, and the NLRP3 inflammasome where/ndata supports further progress into clinical development. We/nare excited by the prospects offered by these novel drugs/nand look